Merck Life Science Technologies (Nantong) Co., Ltd.March 14, 2025

FDA 483 - Merck Life Science Technologies (Nantong) Co., Ltd. - March 14, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Merck Life Science Technologies (Nantong) Co., Ltd.

Record Details

An FDA inspection of Merck life Science Technologies (Nantong) Co. Ltd, an excipients and API manufacturer, revealed significant quality control deficiencies. The firm failed to thoroughly investigate customer complaints and deviations, lacked adequate procedures to prevent microbiological contamination of non-sterile products, and had an insufficient stability program. Additionally, the company did not base material sampling amounts on appropriate criteria.

Company: Merck Life Science Technologies (Nantong) Co., Ltd.
Inspection Date: March 14, 2025
Product Type: Drugs
Office: Office of Inspections and Investigations
Person: Jose M. Cayuela

Open in Dashboard

ID · c60898bc-ea02-4476-adfa-14e5848fe394